Bionas signs service contract with Solvay Pharmaceuticals
3 October 2007
Bionas GmbH, a specialist in in-vitro profiling of cellular metabolic
activity, has signed a service contract with German firm Solvay
Pharmaceuticals GmbH. The contract covers the metabolic profiling of several
drug candidates identified in the context of Solvay's obesity research
Solvay has selected the Bionas 2500 analysing system because it allows
monitoring of both acute and chronic effects of drug candidates in different
cell types thanks to a proprietary perfusion system. Besides the long-term
observation of cells under close to in vivo conditions, the observation of
regeneration effects is also possible.
"The Bionas instrument is a valuable tool for compound ranking and helps
us select the most promising compounds for further development," says Dr.
Michael Firnges at Solvay Pharmaceuticals GmbH.
The Bionas system is a bench-top instrument that allows the simultaneous,
label-free and high-content analysis of three metabolic parameters, such as
acidification, oxygen consumption and adhesion of living cells. The Bionas
instrument has been also selected by Solvay Pharmaceuticals Research
Laboratories (Weesp, Netherlands) for target validation studies.
Save this page on del.icio.us